YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer
Cancer Letters · 2024-10 · 602 · 217197
DOI: 10.1016/j.canlet.2024.217197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-10. Verfasst von Borui Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, …. Hauptthemen laut MEDLINE: beta Catenin, Carcinoma, Pancreatic Ductal, Deoxycytidine, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Municipality Science and Technology Commission, Shanghai Municipal Natural Science Foundation, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is highly malignant and has a poor prognosis, without effective therapeutic targets in common gene mutations. Gemcitabine, a first-line chemotherapeutic for PDAC, confers
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Shanghai Pancreatic Cancer…
- Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, QLD 4067, Australia.
- Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Förderung
- Shanghai Municipality Science and Technology Commission
- Shanghai Municipal Natural Science Foundation
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
Zitieren
APA
Li, B., Xing, F., Wang, J., Wang, X., Zhou, C., Fan, G., Zhuo, Q., Ji, S., Yu, X., Xu, X., Qin, Y., & Li, Z. (2024). YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Cancer Letters, 602, 217197. https://doi.org/10.1016/j.canlet.2024.217197
Vancouver
Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, et al. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Cancer Letters. 2024;602:217197. doi:10.1016/j.canlet.2024.217197
BibTeX
@article{Li2024,
author = {Li, Borui and Xing, Faliang and Wang, Jingyi and Wang, Xiaohong and Zhou, Chenjie and Fan, Guixiong and Zhuo, Qifeng and Ji, Shunrong and Yu, Xianjun and Xu, Xiaowu and Qin, Yi and Li, Zheng},
title = {YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer},
journal = {Cancer Letters},
year = {2024},
volume = {602},
pages = {217197},
doi = {10.1016/j.canlet.2024.217197}
}
EUVIMED